Abstract
Carbonic anhydrase IX (CA IX) is a tumor associated protein, since it is highly expressed in a multitude of carcinomas, while it is present in a limited number of normal tissues. It is a multi-domain protein consisting of an N-terminal proteoglycan-like (PG) domain, a catalytic domain, a trans-membrane portion (TM) and an intracytoplasmatic (IC) segment. These domains have peculiar biochemical and physiological features. Among these, only the PG domain is unique among the CA family. This review focuses on the most recent molecular and catalytic features uncovered of this enzyme, the role of its different domains in tumor physiology, and its three dimensional structure which has recently been solved. In addition, we present recent advances in the development of antibodies and small inhibiting molecules able to target CA IX for diagnostic and therapeutic applications.
Keywords: Anti-tumor drugs, carbonic anhydrase IX, inhibitors, monoclonal antibody, structure based drug design, Carbonic anhydrase, tumor, intracytoplasmatic, enzyme, carcinomas
Current Medicinal Chemistry
Title: Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Volume: 19 Issue: 6
Author(s): S. M. Monti, C. T. Supuran and G. De Simone
Affiliation:
Keywords: Anti-tumor drugs, carbonic anhydrase IX, inhibitors, monoclonal antibody, structure based drug design, Carbonic anhydrase, tumor, intracytoplasmatic, enzyme, carcinomas
Abstract: Carbonic anhydrase IX (CA IX) is a tumor associated protein, since it is highly expressed in a multitude of carcinomas, while it is present in a limited number of normal tissues. It is a multi-domain protein consisting of an N-terminal proteoglycan-like (PG) domain, a catalytic domain, a trans-membrane portion (TM) and an intracytoplasmatic (IC) segment. These domains have peculiar biochemical and physiological features. Among these, only the PG domain is unique among the CA family. This review focuses on the most recent molecular and catalytic features uncovered of this enzyme, the role of its different domains in tumor physiology, and its three dimensional structure which has recently been solved. In addition, we present recent advances in the development of antibodies and small inhibiting molecules able to target CA IX for diagnostic and therapeutic applications.
Export Options
About this article
Cite this article as:
M. Monti S., T. Supuran C. and De Simone G., Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs, Current Medicinal Chemistry 2012; 19 (6) . https://dx.doi.org/10.2174/092986712799034851
DOI https://dx.doi.org/10.2174/092986712799034851 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Evaluating Gene Delivery Using N-triethyl Chitosan Nanoparticles to AsPC-1 Cells and Predicting the Relation between Transfection, Cytotoxicity and Charge Ratio of Nanoparticles Via Mathematical Models
Drug Delivery Letters Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Prokaryotic Arsenate Reductase Enhances Arsenate Resistance in Mammalian Cells
Recent Patents on Food, Nutrition & Agriculture Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Peroxisome Proliferator-activated Receptor-γ As A Novel and Promising Target For Treating Cancer <i>Via</i> Regulation of Inflammation: A Brief Review
Mini-Reviews in Medicinal Chemistry A Survey on Machine Learning Based Medical Assistive Systems in Current Oncological Sciences
Current Medical Imaging Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design